Antihistamines in seasonal allergic rhinitis from a position of evidential medicine

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


The article considers I and II generation of antihistamines (AGs), which are used today in medical practice. The advantages of nonsedative II generation of AGs, especially socalled active metabolites (fexofenadine, cetirizine, levocetirizine, desloratadine) are emphasized. Currently, AGs, such as fexofenadine is deservedly regarded. This is one of the most effective H1AG for therapeutic practice that combines high efficacy and safety. This is the first choice treatment for allergic rhinitis patients.

Restricted Access

A V Karaulov

I.M. Sechenov First Moscow State Medical University

Email: drkaraulov@mail.ru

  1. Sackett D.L., Rosenberg W.M., Gray J.A. et al. Evidence-based medicine: what it is and what it isn’t. BMJ. 1996, v. 312, p. 71-72.
  2. Караулов А.В. Врач должен мыслить иммунологически. Врач. 1998, № 6, с. 4-5.
  3. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт». 1998, 252 с.
  4. Караулов А.В. Фенистил: эффективность и безопасность в сравнении с другими антигистаминными препаратами. Клин. фармакол. и тер. 1996, № 5, с. 82.
  5. Коровкина Е.С., Курбачева О.М., Ильина Н.И. Стандартные подходы к диагностике и лечению аллергического ринита. Росс. Аллерголог. Журн. 2005, № 3, с. 321-326.
  6. Church M.K., Maurer M., Simons F.E.R., Bindslev-Jensen C., van Cauwenberge P., Bousquet J. et al. Risk of first generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010, v. 65 (4), p. 459-466.
  7. Караулов А.В., Сидоренко И.В., Захаржевская Т.В., Трескунов В.К. Антигистаминные препараты в лечении аллергических заболеваний у детей. Росс. Аллерголог. Журн. 2005, № 2, с. 81-83.
  8. EAACI/GAXEN/EDF guideline: management of urticaria. Allergy. 2006), v. 61, p. 321-331.
  9. Finkle WD., Adams J.L., Greenland S., Melmon K.L. Increased risk of serious injury following an initial prescription for diphenhydramine. Ann. Allergy Asthma lmmunol. 2002, v. 89, p. 244-250.
  10. Vena G.A., Cassano N., Buquicchio R., Ventura MT Antiinflammatory effects of H1-antihistamines. Clinical and immunological relevance. Curr. Pharm. Des. 2008, v. 14, p. 2902-2911.
  11. Инструкция по медицинскому применению препарата Телфаст РУ ПN016292/01-040411.
  12. Markham A., Wagstaff A.J. Fexofenadine. Adis new drug profile. Drug. 1998, v. 55, p. 269-274.
  13. Allegra (fexofenadine hydrochloride) [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2007.
  14. Goro Takahashi, Zensei Matsuzaki, Atsushi Okamoto, Eiko Ito, Tomokazu Matsuoka, Takeo Nakayama, Keisuke Masuyama. A Randomized Control Trail of Stepwise Treatment with Fluticasone Propionate Nasal Spray and Fexofenadine Hydrochloride Tablet for Seasonal Allergic Rhinitis Allergology International. 2012, v. 61, p. 155-162.
  15. Назарова Е.В., Ильина Н.И. Аллергический ринит: актуальные подходы к диагностике и лечению. Эффективная фармакотерапия. Аллергол. и иммунол. 2012, № 2, c. 18-24.
  16. Караулов А.В., Сидоренко И.В., Босенко Ю.А. Распространенность и клинические особенности аллергического ринита у детей 1,5-4 лет. Росс. Аллерголог. Журн. 2007, № 4, с. 42-47.
  17. Хаитов Р.М., Ильина Н.И. Аллергология. Клинические рекомендации. ГЭОТАР-Медиа. 2009, 249 с.
  18. Abdelaziz M.M., Devalia J.L., Khair O.A. et al. Effect of fexofenadine on eosinofil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 1998, v. 101, No. 3, p. 410-420.
  19. Compalati E., Baena-Cagnani R., Penagos M. et al. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int. Arch. Allergy Immunol. 2011, v. 156 (1), p. 1-15.
  20. Ralph Mösgesl, Walter Lehmacherl, Norbert Pasch2, Julia Vent. Assessment ofthe Antiobstructive Effect of Fexofenadine on Nasal Allergy Challenge in Patients with Seasonal Allergic Rhinitis. Asian Pacific Journal of Allergy and Immunology. 2009, v. 27, p. 3-9.
  21. Claus Bachert. A Review of the efficacy of Desloratadine, Fexofenadine and Levocetirizine in the treatment of Nasal congestion in patients with Allergic Rhinitis. Clinical Therapeutcs. 2009, v. 3 (5), p. 921-944.
  22. Pratt C., Mason J., Russell T., Ahlbrandt R. Effect of fexofenadine HCI on corrected QT interval (QTc). Paper presented at the Congress of European Academy Of Allergology and Clinical Immunology. Rhodos, Greece, June 1997. 23. Graft D.F., Bernstein D.I., Goldsobel A., Meltzer E.O., Portnoy J., Long J. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2001, Jul., v. 87 (1), p. 22-26.
  23. Graft D.F., Bernstein D.I., Goldsobel A. et al. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2001, v. 87 (1), p. 22-26.
  24. Захаржевская Т.В., Сидоренко И.В., Трескунов В.К., Караулов А.В. Возможности использования нового назального спрея назаваль в лечении и профилактике аллергического ринита. Рос. Аллерголог. Журн. 2009, № 4, с. 82-86.

Views

Abstract - 5

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2013 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies